Journal
TRENDS IN CANCER
Volume 7, Issue 8, Pages 682-699Publisher
CELL PRESS
DOI: 10.1016/j.trecan.2021.02.004
Keywords
-
Categories
Funding
- European Research Council (ERC) [771486MetaRegulation]
- Fonds Wetenschappelijk Onderzoek (FWO) research projects
- KU Leuven Methusalem Co-Funding
- Fonds Baillet Latour
- Associazione Italiana Ricerca sul Cancro (AIRC) [19515]
- Associazione Italiana per la Ricerca sul Cancro (AIRC) [24132]
- University of Florence
Ask authors/readers for more resources
This study emphasizes the important role of amino acid metabolic reprogramming in cancer therapy, with amino acids playing a crucial role in acquiring resistance to anticancer drugs, especially in terms of the resistance of cancer stem cells.
Overcoming anticancer drug resistance is a major challenge in cancer therapy, requiring innovative strategies that consider the extensive tumor heterogeneity and adaptability. We provide recent evidence highlighting the key role of amino acid (AA) metabolic reprogramming in cancer cells and the supportive microenvironment in driving resistance to anticancer therapies. AAs sustain the acquisition of anticancer resistance by providing essential building blocks for biosynthetic pathways and for maintaining a balanced redox status, and modulating the epigenetic profile of both malignant and non-malignant cells. In addition, AAs support the reduced intrinsic susceptibility of cancer stem cells to antineoplastic therapies. These findings shed new light on the possibility of targeting non-responding tumors by modulating AA availability through pharmacological or dietary interventions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available